Biopharma
|
May 27, 2025
Fresenius Receives Positive CHMP Opinion for their Denosumab Biosimilar Candidates
Fresenius announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for the marketing authorization of its biosimilar candidates to Prolia® (denosumab) and Xgeva® (denosumab).